display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced OC (mOC) - 1st line (L1)
metastatic/advanced OC (mOC) - 1st line (L1)
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel AGO-OVAR 2.29/ENGOT-ov34

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons